In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Elevate Therapeutics, the U.S. subsidiary of HLB, has initiated a global Phase 2 clinical trial to expand the tumor-agnostic indication for its FGFR2 ...
Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Notably, Insilico’s self-developed Chemistry42 played a crucial role in this research by generating the pyrrolopyrazine carboxamide core as a starting point for further molecular design. Moreover, ...
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are ...
Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma Recurrent nonkinase domain FGFR VUS variants were collected from the Catalog of Somatic Mutations in Cancer and their ...
First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa, FloridaGlobal multi-site study includes locations in U.S., Korea, the UK, Spain, ...
Bent bone dysplasia (BBD) is a perinatal-lethal skeletal disorder caused by pathogenic FGFR2 mutations that disrupt bone formation, leading to bent long bones, osteopenia, and craniosynostosis. Bent ...
Fibroblast growth factor receptor 2 (FGFR2) is a transmembrane tyrosine kinase that regulates signaling pathways controlling cell survival and proliferation. Dysregulation of FGFR2, through ...
Fibroblast growth factor receptors (FGFRs) are a family of transmembrane tyrosine kinases that orchestrate key cellular processes including proliferation, differentiation, survival and angiogenesis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results